Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179539 | 1.00 | HTR7 (0.70) | HTR7 | |
| SCHEMBL22723071 | 1.00 | HTR7 (0.70) | HTR7 | |
| SCHEMBL31530586 | 1.00 | HTR7 (0.70) | HTR7 | |
| SCHEMBL31530592 | 1.00 | HTR7 (0.70) | HTR7 | |
| SCHEMBL20166479 | 0.91 | HTR7 (0.70) | HTR7 | |
| SCHEMBL31399312 | 0.91 | HTR7 (0.70) | HTR7 | |
| SCHEMBL20181022 | 0.88 | HTR7 (0.72) | HTR7 | |
| SCHEMBL31680072 | 0.88 | HTR7 (0.72) | HTR7 | |
| SCHEMBL31680067 | 0.88 | HTR7 (0.72) | HTR7 | |
| SCHEMBL31680071 | 0.88 | HTR7 (0.72) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541790-B1 | 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS 5-HYDROXYTRYPTAMINE RECEPTOR 7 (5-HT7) MODULATORS FOR TREATING E.G. INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER OR DEPRESSION | UNIV TEMPLE (US) | 2025-09-03 | — | — | EP | claimed |
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-12-08 | — | — | US | claimed |
| EP-3541790-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2019-09-25 | — | — | EP | claimed |
| WO-2018093818-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-24 | — | — | WO | claimed |
| EP-4684837-A1 | NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University of the Commonwealth System of Higher Education (US) | 2026-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858368-B2 | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR7, HTR6, HTR5A | HTR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.